Dyne Therapeutics
About: Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Employees: 173
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 55
24% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 34
22% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $8.75M
4% more funds holding
Funds holding: 194 [Q2] → 201 (+7) [Q3]
1% more capital invested
Capital invested by funds: $3.97B [Q2] → $4.02B (+$56.8M) [Q3]
3.14% less ownership
Funds ownership: 114.8% [Q2] → 111.66% (-3.14%) [Q3]
29% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 10 (-4) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
204%
upside
Avg. target
$49
231%
upside
High target
$55
272%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Luca Issi 36% 1-year accuracy 21 / 58 met price target | 204%upside $45 | Outperform Reiterated | 14 Jan 2025 |
HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 127 / 343 met price target | 272%upside $55 | Buy Reiterated | 13 Jan 2025 |
Chardan Capital Keay Nakae 26% 1-year accuracy 19 / 74 met price target | 238%upside $50 | Buy Maintained | 10 Jan 2025 |
Baird Brian Skorney 21% 1-year accuracy 5 / 24 met price target | 211%upside $46 | Outperform Initiated | 13 Dec 2024 |
Financial journalist opinion
Based on 8 articles about DYN published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET.
Neutral
Zacks Investment Research
4 days ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Positive
Zacks Investment Research
1 week ago
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
2 weeks ago
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.
Negative
Benzinga
3 weeks ago
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
On Friday, Dyne Therapeutics, Inc. DYN revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).
Neutral
GlobeNewsWire
3 weeks ago
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval -
Neutral
GlobeNewsWire
3 weeks ago
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET).
Neutral
GlobeNewsWire
3 weeks ago
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
Positive
Proactive Investors
1 month ago
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need.
Positive
Seeking Alpha
2 months ago
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors.
Charts implemented using Lightweight Charts™